We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell Neoplasms

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01390597
First Posted: July 11, 2011
Last Update Posted: May 17, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group
July 7, 2011
July 11, 2011
May 17, 2017
June 28, 2011
August 28, 2011   (Final data collection date for primary outcome measure)
New somatically mutated genes in T-cell and NK lymphoma samples [ Time Frame: 1 year ]
  • New somatically mutated genes in T-cell and NK lymphoma samples
  • Prognostic significance of mutations in genes and pathways with cell proliferation, survival, and response to epigenetic therapy
Complete list of historical versions of study NCT01390597 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell Neoplasms
The Molecular Mechanisms of Transformation in Peripheral T-cell and NK Lymphomas

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat the cancer.

PURPOSE: This research trial studies biomarkers in tumor tissue samples from patients with peripheral T-cell lymphoma or natural killer cell neoplasms.

OBJECTIVES:

  • To identify mutations in oncogenes and tumor suppressors of peripheral T-cell lymphoma or natural killer (NK) cell neoplasm.
  • To delineate the mechanisms that mediate oncogenic effects and their clinical prognostic significance in these diseases.
  • To perform a comprehensive mutation analysis via whole exome resequencing in a panel of peripheral T-cell or NK lymphomas.

OUTLINE: Fixed paraffin-embedded tumor tissue samples are analyzed for mutations by the Illumina HiSeq platform. Sequencing reads are performed by GAPipeline version 1.5.1 and mapping on the human genome performed using the MAQ software version 0.7.1. Genes harboring validated somatic mutations are then amplified by PCR and analyzed by Sanger resequencing.

Observational
Observational Model: Other
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
Samples from patient enrolled on E2404 from whom samples were submitted for research
Lymphoma
  • Genetic: DNA analysis
  • Genetic: cytogenetic analysis
  • Genetic: gene mapping
  • Genetic: mutation analysis
  • Genetic: polymerase chain reaction
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
32
August 28, 2011
August 28, 2011   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosed with peripheral T-cell lymphoma or natural killer cell neoplasms
  • Available fresh tumor samples from patients treated on ECOG-E2404 and normal DNA (non-ECOG) samples

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
Sexes Eligible for Study: All
18 Years to 120 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01390597
CDR0000703260
ECOG-E2404T1
Not Provided
Not Provided
Not Provided
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Adolfo A. Ferrando, MD, PhD Herbert Irving Comprehensive Cancer Center
Eastern Cooperative Oncology Group
May 2017